Literature DB >> 1824796

Participation of CD4 coreceptor molecules in T-cell repertoire selection.

H S Teh1, A M Garvin, K A Forbush, D A Carlow, C B Davis, D R Littman, R M Perlmutter.   

Abstract

During thymocyte development, progenitor cells bearing both CD4 and CD8 coreceptor molecules mature into functional T lymphocytes that express these proteins in a mutually exclusive way. Although T-cell specificity is determined primarily by the structure of the T-cell antigen receptor (TCR) heterodimer, a developmentally regulated process acts to ensure that cells bearing class II-restricted TCRs are CD4+ and those bearing class I-restricted TCRs express only CD8. To investigate this maturation process, we have engineered transgenic mice in which CD4 is expressed in all thymocyte subsets and in all peripheral T cells. Peripheral CD4+8+ T lymphocytes from these mice react with both class I and class II alloantigens. Moreover, expression of the CD4 transgene disrupts the positive selection of doubly transgenic thymocytes bearing a class I-restricted TCR specific for the male (H-Y) antigen. Hence the CD4 coreceptor participates directly in T-cell repertoire selection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1824796     DOI: 10.1038/349241a0

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  21 in total

1.  Identification and characterization of a T-cell-specific enhancer adjacent to the murine CD4 gene.

Authors:  S Sawada; D R Littman
Journal:  Mol Cell Biol       Date:  1991-11       Impact factor: 4.272

2.  CD4 regulates the efficiency of an endogenous superantigen-induced clonal deletion of TCRV beta 11+ cells in the periphery.

Authors:  S Kubo; A Hasegawa; K Hashimoto; C Shimizu; M Kubo; T Tada; T Nakayama
Journal:  Immunology       Date:  1997-12       Impact factor: 7.397

3.  Differential usage of T-cell receptor V beta gene families by CD4+ and CD8+ T cells in patients with CD8hi common variable immunodeficiency: evidence of a post-thymic effect.

Authors:  R Duchmann; J Jaffe; R Ehrhardt; D W Alling; W Strober
Journal:  Immunology       Date:  1996-01       Impact factor: 7.397

4.  Assembly and crystallization of the complex between the human T cell coreceptor CD8alpha homodimer and HLA-A2.

Authors:  G F Gao; U C Gerth; J R Wyer; B E Willcox; C A O'Callaghan; Z Zhang; E Y Jones; J I Bell; B K Jakobsen
Journal:  Protein Sci       Date:  1998-05       Impact factor: 6.725

5.  Decreased signaling competence as a result of receptor overexpression: overexpression of CD4 reduces its ability to activate p56lck tyrosine kinase and to regulate T-cell antigen receptor expression in immature CD4+CD8+ thymocytes.

Authors:  T Nakayama; D L Wiest; K M Abraham; T I Munitz; R M Perlmutter; A Singer
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

6.  Lymphocyte changes associated with prolongation of cardiac allograft survival in adult mice using anti-CD4 monoclonal antibody.

Authors:  T C Pearson; A R Bushell; C R Darby; L J West; P J Morris; K J Wood
Journal:  Clin Exp Immunol       Date:  1993-05       Impact factor: 4.330

7.  Thymic tumorigenesis induced by overexpression of p56lck.

Authors:  K M Abraham; S D Levin; J D Marth; K A Forbush; R M Perlmutter
Journal:  Proc Natl Acad Sci U S A       Date:  1991-05-01       Impact factor: 11.205

8.  Human CD4 produced in lymphoid cells of transgenic mice binds HIV gp120 and modifies the subsets of mouse T-cell populations.

Authors:  P Forte; A Aiuti; L Pozzi; F Citarella; A Fattorossi; G B Rossi; A Fantoni
Journal:  Immunogenetics       Date:  1993       Impact factor: 2.846

9.  Association of CD8 with p56lck is required for early T cell signalling events.

Authors:  N J Chalupny; J A Ledbetter; P Kavathas
Journal:  EMBO J       Date:  1991-05       Impact factor: 11.598

10.  Altered T cell activation and development in transgenic mice expressing the HIV-1 nef gene.

Authors:  J Skowronski; D Parks; R Mariani
Journal:  EMBO J       Date:  1993-02       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.